In some preclinical studies, anti-VEGF therapy improved vascular pericyte coverage, resulting in a reduction in metastatic cell intravasation, tumor hypoxia, and interstitial fluid pressure and increased delivery, as well as efficacy of cancer therapies (Goel et al., 2011). The gene discussed is VEGFA; the disease is cancer.